Infographics
Explore our summarised infographics.
Showing results for
VOCABRIA + REKAMBYS
The Ask Us study looked at whether healthcare providers are discussing & offering innovative treatment options equitably across diverse populations of people living with HIV.
VOCABRIA + REKAMBYS
Data from LATA, a 96-week, randomised, open-label, non-inferiority trial presented at AIDS 2026
VOCABRIA + REKAMBYS
Data from OPERA head-to-head real world comparison study presented at AIDS 2026
DOVATO
Data from VOGUE head-to-head from AIDS 2026
DOVATO, VOCABRIA + REKAMBYS
Redefining choice early in HIV treatment
VOCABRIA + REKAMBYS
Data from a real-world cohort looking at effectiveness of VOCABRIA + REKAMBYS across a range of BMIs.
DOVATO
Data from PASO DOBLE and a naïve meta-analysis from CROI 2026
DOVATO
5 Years of Clinical and Real World Evidence Data
DOVATO
Data from PASO DOBLE from EACS 2025
DOVATO
Data from VOLITION and D2ARLING from IAS 2025
Other resources
PM-GB-HVX-WCNT-220003 v10 | October 2026
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.
